长非编码RNA作为竞争性内源RNA在黑色素瘤中的研究进展

doi:10.3760/cma.j.cn371439-20210520-00009

摘要/Abstract

摘要：

近年来,长非编码RNA(lncRNA)作为竞争性内源RNA(ceRNA)在黑色素瘤中的研究日益增多。lncRNA在黑色素瘤中呈现高表达或低表达,并通过ceRNA机制竞争性地与miRNA结合,影响miRNA下游靶基因mRNA的表达,从而发挥癌基因或抑癌基因的作用。了解lncRNA作为ceRNA在黑色素瘤中的作用,可为未来黑色素瘤的诊断及治疗靶点研究提供新思路。

关键词: 黑色素瘤, RNA,长链非编码, 微小RNAs, 竞争性内源RNA

Abstract:

In recent years, there has been an increasing number of studies on long non-coding RNAs (lncRNAs) as a competing endogenous RNA (ceRNA) in melanoma. Different lncRNAs show high or low expression in melanoma, and competitively combine with miRNAs through ceRNA mechanism, affecting the expression of downstream target mRNAs, thereby playing the role of oncogenes or tumor suppressor genes. Understanding the role of lncRNA as ceRNA in melanoma can provide new ideas for the diagnosis and treatment of melanoma in the future.

Key words: Melanoma, RNA,long noncoding, MicroRNAs, Competing endogenous RNA

洪安澜, 曹蒙, 王焱, 方方. 长非编码RNA作为竞争性内源RNA在黑色素瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(1): 61-64.

Hong Anlan, Cao Meng, Wang Yan, Fang Fang. Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64.

参考文献 37

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Riefolo M, Porcellini E, Dika E, et al. Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces[J]. Mol Oncol, 2019, 13(1):74-98. DOI: 10.1002/1878-0261.12412. doi: 10.1002/1878-0261.12412 pmid: 30499222
[3]	Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways[J]. Cancer Cell, 2016, 29(4):452-463. DOI: 10.1016/j.ccell.2016.03.010. doi: S1535-6108(16)30092-7 pmid: 27070700
[4]	Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypojournal: the rosetta stone of a hidden RNA language?[J]. Cell, 2011, 146(3):353-358. DOI: 10.1016/j.cell.2011.07.014. doi: 10.1016/j.cell.2011.07.014
[5]	Yu X, Zheng H, Tse G, et al. Long non-coding RNAs in melanoma[J]. Cell Prolif, 2018, 51(4):e12457. DOI: 10.1111/cpr.12457. doi: 10.1111/cpr.12457
[6]	Luan W, Li R, Liu L, et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p[J]. Oncotarget, 2017, 8(49):85401-85414. DOI: 10.18632/oncotarget.19910. doi: 10.18632/oncotarget.19910
[7]	Cantile M, Scognamiglio G, Marra L, et al. HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease[J]. J Cell Physiol, 2017, 232(12):3422-3432. DOI: 10.1002/jcp.25789. doi: 10.1002/jcp.25789 pmid: 28067428
[8]	Wang P, Hu L, Fu G, et al. LncRNA MALAT1 promotes the proli-feration, migration, and invasion of melanoma cells by downregulating miR-23a[J]. Cancer Manag Res, 2020, 12:6553-6562. DOI: 10.2147/CMAR.S249348. doi: 10.2147/CMAR.S249348 pmid: 32801893
[9]	Li F, Li X, Qiao L, et al. MALAT1 regulates miR-34a expression in melanoma cells[J]. Cell Death Dis, 2019, 10(6):389. DOI: 10.1038/s41419-019-1620-3. doi: 10.1038/s41419-019-1620-3
[10]	Sun Y, Cheng H, Wang G, et al. Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation[J]. Oncotarget, 2017, 8(2):3509-3518. DOI: 10.18632/oncotarget.13862. doi: 10.18632/oncotarget.13862
[11]	Han C, Tang F, Chen J, et al. Knockdown of lncRNA-UCA1 inhi-bits the proliferation and migration of melanoma cells through modulating the miR-28-5p/HOXB3 axis[J]. Exp Ther Med, 2019, 17(5):4294-4302. DOI: 10.3892/etm.2019.7421. doi: 10.3892/etm.2019.7421
[12]	Chen X, Gao J, Yu Y, et al. Long non-coding RNA UCA1 targets miR-185-5p and regulates cell mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/β-catenin signaling pathway[J]. Gene, 2018, 676:298-305. DOI: 10.1016/j.gene.2018.08.065. doi: 10.1016/j.gene.2018.08.065
[13]	Wei Y, Sun Q, Zhao L, et al. LncRNA UCA1-miR-507-FOXM1 axis is involved in cell proliferation, invasion and G₀/G₁ cell cycle arrest in melanoma[J]. Med Oncol, 2016, 33(8):88. DOI: 10.1007/s12032-016-0804-2. doi: 10.1007/s12032-016-0804-2
[14]	Chen X, Gao G, Liu S, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma[J]. Biomed Res Int, 2017, 2017:7038579. DOI: 10.1155/2017/7038579. doi: 10.1155/2017/7038579
[15]	Wang BJ, Ding HW, Ma GA. Long noncoding RNA PVT1 promotes melanoma progression via endogenous sponging miR-26b[J]. Oncol Res, 2018, 26(5):675-681. DOI: 10.3727/096504017X-14920318811730. doi: 10.3727/096504017X-14920318811730
[16]	Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells[J]. Oncol Lett, 2019, 18(5):4393-4402. DOI: 10.3892/ol.2019.10848. doi: 10.3892/ol.2019.10848 pmid: 31611948
[17]	Liu W, Feng Q, Liao W, et al. TUG1 promotes the expression of IFITM3 in hepatocellular carcinoma by competitively binding to miR-29a[J]. J Cancer, 2021, 12:6905-6920. DOI: 10.7150/jca.57477. doi: 10.7150/jca.57477
[18]	Yuan JB, Gu L, Chen L, et al. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis[J]. Mol Ther Oncolytics, 2021, 22:36-51. DOI: 10.1016/j.omto.2021.04.008. doi: 10.1016/j.omto.2021.04.008
[19]	Liu Q, Zhang W, Luo L, et al. Long noncoding RNA TUG1 regulates the progression of colorectal cancer through miR-542-3p/TRIB2 axis and Wnt/β-catenin pathway[J]. Diagn Pathol, 2021, 16(1):47. DOI: 10.1186/s13000-021-01101-7. doi: 10.1186/s13000-021-01101-7
[20]	Wang Y, Liu G, Ren L, et al. Long non-coding RNA TUG1 recruits miR-29c-3p from its target gene RGS1 to promote proliferation and metastasis of melanoma cells[J]. Int J Oncol, 2019, 54(4):1317-1326. DOI: 10.3892/ijo.2019.4699. doi: 10.3892/ijo.2019.4699
[21]	Long J, Menggen Q, Wuren Q, et al. Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes tumor growth and metastasis through TUG1/miR-129-5p/astrocyte-elevated gene-1 (AEG-1) axis in malignant melanoma[J]. Med Sci Monit, 2018, 24:1547-1559. DOI: 10.12659/msm.906616. doi: 10.12659/msm.906616
[22]	Fan J, Kang X, Zhao L, et al. Long noncoding RNA CCAT1 functions as a competing endogenous RNA to upregulate ITGA9 by sponging miR-296-3p in melanoma[J]. Cancer Manag Res, 2020, 12:4699-4714. DOI: 10.2147/CMAR.S252635. doi: 10.2147/CMAR.S252635
[23]	Lv L, Jia JQ, Chen J. The lncRNA CCAT1 upregulates proliferation and invasion in melanoma cells via suppressing miR-33a[J]. Oncol Res, 2018, 26(2):201-208. DOI: 10.3727/096504017X1-4920318811749. doi: 10.3727/096504017X1-4920318811749
[24]	Pan B, Lin X, Zhang L, et al. Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance[J]. Melanoma Res, 2019, 29(3):254-262. DOI: 10.1097/CMR.0000000000000560. doi: 10.1097/CMR.0000000000000560
[25]	Tian K, Sun D, Chen M, et al. Long noncoding RNA X-inactive specific transcript facilitates cellular functions in melanoma via miR-139-5p/ROCK1 pathway[J]. Onco Targets Ther, 2020, 13:1277-1287. DOI: 10.2147/OTT.S225661. doi: 10.2147/OTT.S225661
[26]	Ma MH, An JX, Zhang C, et al. ZEB1-AS1 initiates a miRNA-mediated ceRNA network to facilitate gastric cancer progression[J]. Cancer Cell Int, 2019, 19:27. DOI: 10.1186/s12935-019-0742-0. doi: 10.1186/s12935-019-0742-0
[27]	Xia W, Jie W. ZEB1-AS1/miR-133a-3p/LPAR3/EGFR axis promotes the progression of thyroid cancer by regulating PI3K/AKT/mTOR pathway[J]. Cancer Cell Int, 2020, 20:94. DOI: 10.1186/s12935-020-1098-1. doi: 10.1186/s12935-020-1098-1 pmid: 32231464
[28]	Wang Q, Zhang R, Liu D. Long non-coding RNA ZEB1-AS1 indicates poor prognosis and promotes melanoma progression through targeting miR-1224-5p[J]. Exp Ther Med, 2019, 17(1):857-862. DOI: 10.3892/etm.2018.7005. doi: 10.3892/etm.2018.7005
[29]	Siena ÁDD, Plaça JR, Araújo LF, et al. Whole transcriptome analysis reveals correlation of long noncoding RNA ZEB1-AS1 with invasive profile in melanoma[J]. Sci Rep, 2019, 9(1):11350. DOI: 10.1038/s41598-019-47363-6. doi: 10.1038/s41598-019-47363-6
[30]	Moradi MT, Fallahi H, Rahimi Z. Interaction of long noncoding RNA MEG3 with miRNAs: a reciprocal regulation[J]. J Cell Biochem, 2019, 120(3):3339-3352. DOI: 10.1002/jcb.27604. doi: 10.1002/jcb.27604
[31]	Al-Rugeebah A, Alanazi M, Parine NP. MEG3: an oncogenic long non-coding RNA in different cancers[J]. Pathol Oncol Res, 2019, 25(3):859-874. DOI: 10.1007/s12253-019-00614-3. doi: 10.1007/s12253-019-00614-3 pmid: 30793226
[32]	Long J, Pi X. lncRNA-MEG3 suppresses the proliferation and invasion of melanoma by regulating CYLD expression mediated by sponging miR-499-5p[J]. Biomed Res Int, 2018, 2018:2086564. DOI: 10.1155/2018/2086564. doi: 10.1155/2018/2086564
[33]	Wu L, Zhu L, Li Y, et al. LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis[J]. Cancer Cell Int, 2020, 20:12. DOI: 10.1186/s12935-019-1087-4. doi: 10.1186/s12935-019-1087-4
[34]	Kolenda T, Rutkowski P, Michalak M, et al. Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor[J]. Oncotarget, 2019, 10(39):3879-3893. DOI: 10.18632/oncotarget.26989. doi: 10.18632/oncotarget.26989 pmid: 31231466
[35]	Yu X, Zheng H, Tse G, et al. CASC2: an emerging tumour-suppressing long noncoding RNA in human cancers and melanoma[J]. Cell Prolif, 2018, 51(6):e12506. DOI: 10.1111/cpr.12506. doi: 10.1111/cpr.12506
[36]	Wang Z, Wang X, Zhou H, et al. Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(3):263-272. DOI: 10.1093/abbs/gmx148. doi: 10.1093/abbs/gmx148
[37]	Zhang Y, Qian W, Feng F, et al. Upregulated lncRNA CASC2 may inhibit malignant melanoma development through regulating miR-18a-5p/RUNX1[J]. Oncol Res, 2019, 27(3):371-377. DOI: 10.3727/096504018X15178740729367. doi: 10.3727/096504018X15178740729367